Vestal Point Capital, LP Uni Qure N.V. Call Options Transaction History
Vestal Point Capital, LP
- $1.21 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding QURE
# of Institutions
148Shares Held
34.1MCall Options Held
1.07MPut Options Held
603K-
Nantahala Capital Management, LLC New Canaan, CT3.09MShares$13.8 Million1.03% of portfolio
-
683 Capital Management, LLC New York, NY1.98MShares$8.85 Million0.88% of portfolio
-
Black Rock Inc. New York, NY1.86MShares$8.34 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.52MShares$6.8 Million0.0% of portfolio
-
Schroder Investment Management Group London, X01.24MShares$5.56 Million0.01% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $209M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...